Beranda › Penyakit Sel Sabit › Ohio
Uji klinis Penyakit Sel Sabit di Ohio
22 studi untuk Penyakit Sel Sabit mencari peserta di lokasi di Ohio.
Kota di Ohio
Teks studi resmi (Bahasa Inggris)
A Phase 1b, Open-Label Study of DISC-3405 in Participants With Sickle Cell Disease (SCD)
- Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Sep 2026 · NCT07187973A Study to Evaluate How Well Etavopivat Works in People With Sickle Cell Disease
- Univ Hosp Cleveland Med Ctr, Cleveland
- Ohio State Univ Wexner Med Ctr, Columbus
Menerima pesertaFase 3
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 17 Sep 2026 · NCT06612268Sickle Cell Disease Biofluid Chip Technology (SCD BioChip)
- University Hospitals Case Medical Center, Cleveland
Menerima pesertaStudi observasionalSukarelawan sehat diterima
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 11 Sep 2026 · NCT02824471A Study to Evaluate BMS-986470 in Healthy Volunteers and Participants With Sickle Cell Disease
- Local Institution - 0028, Cleveland
Menerima pesertaFase 1/2Sukarelawan sehat diterima
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 18 Agu 2026 · NCT06481306ATHN Transcends: A Natural History Study of Non-Neoplastic Hematologic Disorders
- Akron Children's Hospital - Showers Center for Cancer & Blood Disorders, Akron
- Cincinnati Children's Hospital Medical Center, Hemophilia & Thrombosis Center, Cincinnati
- University of Cincinnati Medical Center Hemophilia Treatment Center, Cincinnati
- dan 5 lainnya
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 17 Agu 2026 · NCT04398628Safety, Efficacy, and Pharmacokinetics of CSL889 in Adults and Adolescents With Sickle Cell Disease During Vaso-Occlusive Crisis
- University of Cincinnati, Cincinnati
- The Ohio State University, Columbus
Menerima pesertaFase 2
Usia 12 ke atas · Semua jenis kelamin · Diperbarui 14 Agu 2026 · NCT06699849Integrative Medicine in Pain Management in Sickle Cell Disease, 2.0
- University of Cincinnati College of Medicine, Cincinnati
Menerima pesertaSukarelawan sehat diterima
Usia 14 hingga 80 · Semua jenis kelamin · Diperbarui 12 Agu 2026 · NCT06725550Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD)
- Ohio State University, Columbus
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT07224360Gene Correction in Autologous CD34+ Hematopoietic Stem Cells (HbS to HbA) to Treat Severe Sickle Cell Disease
- Nationwide Children's Hospital, Columbus
Menerima pesertaFase 1/2
Usia 12 hingga 50 · Semua jenis kelamin · Diperbarui 2 Jul 2026 · NCT04819841Hydroxyurea Exposure Limiting Pregnancy and Follow-Up Lactation
- Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaStudi observasional
Semua usia · Semua jenis kelamin · Diperbarui 18 Jun 2026 · NCT04093986Comparing the Effectiveness of Matched Related Donor Hematopoietic Stem Cell Transplantation to Disease Modifying Therapy in Pediatric Patients With Sickle Cell Disease
- Nationwide Children's Hospital (NT-DMT), Columbus
Menerima pesertaStudi observasional
Usia 3 hingga 20 · Semua jenis kelamin · Diperbarui 4 Jun 2026 · NCT06941389A Socio-ecological Approach for Improving Self-management in Adolescents With SCD
- Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima peserta
Usia 13 hingga 21 · Semua jenis kelamin · Diperbarui 11 Mei 2026 · NCT06290401Delivering Patient-Facing Evidence-Based Guidelines Through mHealth to Adults With Sickle Cell Disease
- The Ohio State University Medical Center, Columbus
Menerima peserta
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 23 Mar 2026 · NCT06919224Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial
- Cincinnati Children's Hospital, Cincinnati
Menerima pesertaFase 2
Usia 15 hingga 40 · Semua jenis kelamin · Diperbarui 13 Mar 2026 · NCT06260891Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease
- Nationwide Children's Hospital, Columbus
Menerima pesertaFase 2
Usia 2 hingga 25 · Semua jenis kelamin · Diperbarui 10 Mar 2026 · NCT03587272MULTIsite Feasibility of MUSIc Therapy to Address Quality Of Life in Sickle Cell Disease
- UH Seidman Cancer Center Adult SCD Clinic or UH Rainbow Babies and Children's Hospital Sickle Cell Anemia Center, Cleveland
Menerima peserta
Usia 14 ke atas · Semua jenis kelamin · Diperbarui 29 Jan 2026 · NCT06853158A Long-term Follow-up Study in Patients Who Received BEAM-101
- University Hospitals Clevland Medical Center, Cleveland
- The Clevland Clinic Foundation, Cleveland
Menerima pesertaStudi observasional
Usia 14 hingga 37 · Semua jenis kelamin · Diperbarui 28 Jan 2026 · NCT07373639Verifying Antibodies After Live Immunization Delivery (VALID): A Study of Measles Vaccine Immunogenicity in Children With Sickle Cell Disease
- Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaStudi observasional
6 Months – 6 Years · Semua jenis kelamin · Diperbarui 21 Jan 2026 · NCT07356050Integrative Training Program for Pediatric Sickle Cell Pain
- Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima peserta
Usia 12 hingga 18 · Semua jenis kelamin · Diperbarui 14 Nov 2025 · NCT06691867Effectiveness of Nontraditional Hydroxyurea Algorithms: Novel and Clinical Evaluations (ENHANCE)
- Cincinnati Children's Hospital Medical Center, Cincinnati
Menerima pesertaFase 4
6 Months · Semua jenis kelamin · Diperbarui 16 Sep 2025 · NCT07177300HPC Offered for PRESERVE Expansion
- The Ohio State University Medical Center, Columbus
Menerima pesertaStudi observasional
Usia 12 hingga 80 · Semua jenis kelamin · Diperbarui 28 Agu 2025 · NCT07145411Recruitment and Engagement in Care to Impact Practice Enhancement (RECIPE) for Sickle Cell Disease
- Cleveland Clinic, Cleveland
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Jun 2025 · NCT06385886Dari ClinicalTrials.gov, data diambil 5 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.